Results 81 to 90 of about 101,135 (306)

Antiplatelet therapy in elderly [PDF]

, 2008
The aim of our study was to determine the efficacy of antiplatelet therapy in elderly and polymorbid patients. We were interested to know whether selected laboratory parameters, co-existing conditions, and concomitant therapy may affect the antiplatelet ...
Paluch, Zoltán
core  

Republished: Antiplatelet therapy for secondary prevention of coronary artery disease

, 2015
The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core   +1 more source

Subgroup based on single antiplatelet therapy (SAPT) choice following dual antiplatelet therapy (DAPT) in the short DAPT arm.

, 2023
Subgroup based on single antiplatelet therapy (SAPT) choice following dual antiplatelet therapy (DAPT) in the short DAPT arm.
Kevin R. Bainey (11060747), Andrew Yan (2422876), Blair J. MacDonald (16920547), David Bewick (16920550), Ricky D. Turgeon (6411179), Guillaume Marquis-Gravel (4044482)   +5 more
core   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

British Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga, Stefano Agliardi, Riccardo Giossi, Alice Schianchi, Alessandra Romandini, Thomas Virdis, Silvia Nerini Molteni, Maria Luisa De Angelis, Stefania Paccagnini, Cecilia Gechtman, Alice Proto, Marco Fossati, Silvia Oliveri, Giulia Angela Pattarino, Elena Altieri, Agnese Graziosi, Arianna Pani, Romano Danesi, Stefano Martinelli, Costantino De Giacomo, Francesco Scaglione   +20 more
wiley   +1 more source

Effect of prior antiplatelet therapy on major adverse cardiac events in patients diagnosed with infective endocarditis: Population-based retrospective cohort study

Journal of Medical Sciences, 2019
Background: Infective endocarditis (IE) occurs with an incidence of about 3–10 per 100,000 person-years globally. Those with infective endocarditis complicated embolic events have worse outcomes.
Tsung-Ta Chiang, Jia-Hong Chen, Jun-Ren Sun, Ti Yin, Yung-Chih Wang, Ya-Sung Yang, Te-Yu Lin, Sheng-Kang Chiu, Kuo-Ming Yeh, Ning-Chi Wang, Jung-Chung Lin, Fung-Yee Chang   +11 more
doaj   +1 more source

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics

, 2015
Amber L Beitelshees,1,* Deepak Voora,2,* Joshua P Lewis,1,* 1Program for Personalized and Genomic Medicine and Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA; 2Center for Applied Genomics
Beitelshees AL, Lewis JP, Voora D
core  

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source

Racial and ethnic differences in restarting antiplatelet therapy in patients with primary intracranial hemorrhage: a systematic review and meta-analysis

BMC Neurology
Background There has long been clinical disagreement over the resumption of antiplatelet therapy in patients with primary intracranial hemorrhage (ICH).
Xuechang Wang, Ting Chen, Junning Zhou, Yuan Qin   +3 more
doaj   +1 more source

Individualized antiplatelet therapy

, 2009
SummarySafeguarding of antiplatelet drug efficacy represents a cornerstone for the optimal treatment of patients with symptomatic coronary artery disease requiring coronary interventions.
T. Geisler, M. Gawaz
core   +1 more source

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [PDF]

, 2002
OBJECTIVE: To determine the effects of antiplatelet therapy among patients at high risk of occlusive vascular events. DESIGN: Collaborative meta-analyses (systematic overviews).
M. Catalano, Mccollum, Charles, Collaboration, Antithrombotic Trialists', Antithrombotic Trialists' Collaboration, Antithrombotic Trialists', Baigent, C, Collins, R, McCollum, CN, Antithrombotic Trialists' Collaboration, Sudlow, C, Peto, R   +9 more
core   +1 more source